ArticleAbdominal radiology (New York)2025
Efficacy and safety of microwave ablation in solitary kidney patients with T1a small renal masses.
Article in Abdominal radiology (New York), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectivesTo assess the safety and efficacy of using microwave ablation (MWA) to treat solitary kidney (SK) patients with T1a renal cell carcinoma (RCC).
methodsRetrospective analysis of a prospectively maintained database identified patients with T1a RCC with either congenital or acquired SK. Estimated glomerular filtration rate (eGFR) was calculated from serum creatinine before MWA and after at 6 and 12 months post-procedure. The local recurrence-free survival (LRFS), metastatic-recurrence free survival (MRFS), cancer-specific survival, and overall survival were analyzed with the Kaplan-Meier method.
resultsA total of 26 patients met inclusion criteria, including 3 congenital and 23 acquired SK patients. eGFR was lower at both 6 and 12 months post-procedure compared to pre-procedure, with the congenital SK group having a more pronounced reduction in eGFR at both post-procedure timepoints. Median follow-up time was 28.6 months (IQR 12.4-55.4). Four patients (15.4%) experienced local recurrence. For LRFS, mean survival time was 69.4 months. There were 5 patients (19.2%) that experienced metastatic recurrence, with median and mean survival time at 101.1 and 82.0 months, respectively. The mean time for RCC-specific survival was 94.7 months, while median and mean time for overall survival was 43.1 and 61.7 months, respectively.
conclusionWith a moderate reduction in renal function and a comparable rate of local recurrence compared to prior literature, this work demonstrates that MWA remains a viable alternative to more invasive techniques, particularly for high-risk SK patients with RCC. Our work highlights the need for further research on effectiveness of MWA in cancer control and preservation of renal function in larger cohorts of SK patients over extended follow-up times.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.